Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May;28(5):1439-1440.
doi: 10.1111/ene.14768. Epub 2021 Feb 18.

The paradigm shift in long-term treatments for migraine prevention

Raffaele Ornello  1 , Simona Sacco  1
Affiliations
Editorial

The paradigm shift in long-term treatments for migraine prevention

Raffaele Ornello et al. Eur J Neurol. 2021 May.
No abstract available

Keywords: migraine prevention; monoclonal antibodies.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Tiseo C, Ornello R, Pistoia F, Sacco S. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain. 2019;20(1):49. https://doi.org/10.1186/s10194-019-1000-5
    1. Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28:1716-1725. https://doi.org/10.1111/ene.14715.
    1. García-Azorin D, Santos-Lasaosa S, Gago-Veiga AB, Viguera Romero J, Guerrero-Peral AL. Real world preventative drug management of migraine among Spanish neurologists. J Headache Pain. 2019;20(1):19. https://doi.org/10.1186/s10194-019-0971-6
    1. Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470-485. https://doi.org/10.1177/0333102416678382
    1. Winner PK, Blumenfeld AM, Eross EJ, et al. Long-term safety and tolerability of OnabotulinumtoxinA treatment in patients with chronic migraine: results of the COMPEL study. Drug Saf. 2019;42(8):1013-1024. https://doi.org/10.1007/s40264-019-00824-3

MeSH terms

Substances

LinkOut - more resources